First-line immune checkpoint blockade for advanced Non-Small-Cell Lung Cancer: travelling at the speed of light

First major improvements in NSCLC care have been achieved by the identification of targetable oncogenic alterations together with specific targeted therapies. However, the vast majority of Caucasian lung cancer patients do not present with a targetable driver mutation and standard cytotoxic chemotherapy (ChT) and anti-angiogenic strategies represented the cornerstones of systemic lung cancer treatment for decades. Nowadays, the treatment of advanced Non-Small-Cell Lung Cancer (NSCLC) is radically transforming.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research